273 results about "Polysorbates" patented technology

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.

An antimicrobial moisturizing composition includes benzethonium chloride or benzalkonium chloride, a non-benzyl cationic surfactant, and an aqueous carrier. The composition of the present invention provides a significant and unexpected reduction of irritation, inflammation, dryness and/or redness, all issues associated with known alcohol-based skin disinfectants. In particular, the present invention provides a stable, aesthetically-pleasing, long-lasting, and moisturizing antimicrobial composition that is substantially free of ethanol, polysorbates, and anionic compounds that are known to inhibit the activity of benzethonium chloride or benzalkonium chloride.

Pharmaceutical formulations comprising cabazitaxel, solubilizer, tocopherol polyethylene glycol succinate (TPGS), one or more hydrotropes, optionally one or more agents having a pK_a of about 3 to about 6, and optionally one or more antioxidizing agents, wherein the formulations are substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol or ethanol. Pharmaceutical formulations may alternatively comprise cabazitaxel, solubilizer, optionally one or more agents having a pK_a of about 3 to about 6, and optionally one or more antioxidizing agents, wherein the formulations are substantially free of polysorbates and polyethoxylated castor oil. These formulations may be combined with a diluent, which comprises TPGS and one or more hydrotropes. Methods of administering the cabazitaxel formulations include combining the formulations with an infusion solution.

The invention relates to a formula and method for immobilizing a tick sample for scanning electron microscopy, which belongs to the technical field of methods for immobilizing samples for scanning electron microscopy. The immobilization formula comprises a PBS buffer solution, polysorbate and glutaraldehyde, and a glutaraldehyde immobilization liquid is prepared from the above-mentioned components. The method comprises the following steps: (1) observing whether host tissue is left in basis capituli of the tick sample and if so, removing the host tissue; (2) cleaning the surface of the tick sample; (3) immobilizing the tick sample at room temperature by using the glutaraldehyde immobilization liquid; (4) carrying out gradient dehydration with ethanol on the immobilized tick sample; (5) putting the tick sample into mixed liquor of absolute ethyl alcohol and acetone for displacement, and then putting the tick sample into acetone for displacement; and (6) drying the tick sample in a vacuum freeze drying instrument for drying and spraying gold on the tick sample. During scanning electron microscopic observation, the phenomenon of fuzzy and foggy images or incapable imaging due to ionization discharging of the sample as water vapor produced after electron beam bombardment of the sample encounters high-energy electron streams is prevented.

The invention relates to a pharmaceutical composition having the following constituents: azelaic acid, polyacrylic acid, triacylglyceride, propylene glycol, polysorbate, soya lecithin, water and salts. The composition is a hydrogel which is suited for the treatment of rosacea, presbyderma, melasma or skin irritations.

The invention discloses a preparation method of high-purity 1,4-sorbitan, which is characterized by taking D-sorbitol as a raw material through dewatering twice and three times of crystallization. The method comprises the following steps of: (1) adding polyatomic alcohol in a reaction vessel; (2) stirring, heating and decompressing for removing free water; (3) cooling down and adding an acidic catalyst; (4) stirring, heating and decompressing for dehydrating a molecule of water; (5) neutralizing and filtering for separating the catalyst; (6) decolorizing; (7) carrying out crystallization for three times in lower alcohol to prepare the 1,4-sorbitan with more than 99% of content. The preparation method fills up the blank of 1,4-sorbitan industrial production technique; the prepared 1,4-sorbitan can be used for synthesizing high-purity surfactants, such as Span, Tween, sorbitan fatty acid ester or polysorbate and the like; and the polysorbate-80 synthesized by the prepared 1,4-sorbitan can satisfy the standard of injection-level pharmaceutic adjuvant.

The invention discloses an effective skin care product having effects of whitening skin and removing freckles and a preparation method of the skin care product. The skin care product is prepared from raw materials in percentage by weight as follows: 5%-8% of Asian Betula alba juice, 2.5%-4.5% of the other effective skin care product additive, 10%-12% of glycerin, 1.5%-2.0% of ceramide 3, 0.8%-1.5% of sodium hyaluronate, 1.5%-2.5% of polysorbate -20 and 73%-78.7% of water, wherein the other effective skin care product additive is prepared from raw materials in percentage by weight as follows: 5%-8% of a glycyrrhiza glabra root extract, 3%-5% of a strawberry extract, 3%-7% of arbutin and 4.5%-7.5% of aloe vera leaf juice. Trials on the effective skin care product having effects of whitening skin and removing freckles by consumers find that the skin care product has effects of whitening skin, removing freckles and resisting oxidation; during the trials, feedback of trial allergic reactions is not received, and the skin care product is suitable for people with various skin types at ages prone to freckles (20-50 years old).

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.

The invention discloses a cream for chap removal, which is composed of a water phase, an oil phase and a functional phase, wherein in parts by weigh, the water phase is composed of 45-85 parts of water, 0.1-0.5 part of allantoin and 0.05-0.2 part of diazolidinyl urea, the oil phase is composed of 0.5-1.5 parts of cetostearyl alcohol, 1-3 parts of glyceryl stearate, 0.5-1.5 parts of PEG-100 stearate, 2.5-5 parts of glycerin, 1-5 parts of polydimethylsiloxane, 2.5-5 parts of propylene glycol, 1-3 parts of isopropyl palmitate, 1-3 parts of petrolatum, 0.5-1.5 parts of polysorbate-60, 5-15 parts of mineral oil, 0.1-0.3 part of methylparaben, and 0.05-0.15 part of propyl hydroxybenzoate; and the functional phase is composed of 1-4 parts of one or more of ammonium polyacrylate, C13-16 isoparaffin, and laureths-25, 0.15-0.45 part of essence and 0.25-0.75 part of vitamin E. Experiments show that the cream both has the functions of water locking and moisturizing and has the effects of chap prevention and chap removal, therefore, the cream has a good market prospect.

A topical administration carrier composition including water, glycerin and polysorbate, suitable for use with compositions containing active ingredients such as minoxidil that are susceptible to volatilization and transdermal penetration in application to the body. The carrier formulation retards the evaporative and systemic migration losses of the active ingredient composition, to provide sustained topical action, in relation to formulations lacking the components of the inventive composition.

The invention relates to the processing of substances that are not soluble, or soluble with difficulty, in water, in such a manner that, introduced into water or oil, these substances can yield a clear solution and can be easily integrated with finest homogeneous distribution into foodstuff, cosmetics, pharmaceuticals, and nutrient solutions. To achieve that, the invention provides a concentrate, consisting of an active substance from the group, which includes an algae oil, an essential oil, a terpene, phosphatidylserine, an ω 3 fatty acid, lanolin, a linoleic acid triglyceride, citral or tea tree oil, and a surplus amount of a polysorbate with at least two and half times the weight of the active substance.

This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e.g. 50 mg/ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5.5 to about pH 6.5, about 0.01-0.1% polysorbate, and a tonicity modifier that contributes to the isotonicity of the formulation. This liquid formulation is stable at refrigerated temperature (2-8° C.) for at least 1 year, and preferably 2 years. This liquid formulation is suitable for subcutaneous injection. The preferred antibodies include Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; HuEP5C7, a humanized anti-L selectin monoclonal antibody; and Flintozumab, a humanized anti-gamma interferon monoclonal antibody.

The invention discloses high-fat powder grease, which is characterized in that the high-fat powder grease comprises the following components in percent by weight: 81-91 percent of edible grease, 4-10 percent of edible emulsifier, 0.5-3 percent of silicon dioxide and dipotassium phosphate, 1-5 percent of animal and plant protein and 3-10 percent of starch sugar, wherein the edible emulsifier is one of the following matters or mixture of two or more than two of the following matters: monoglycerol/diglycerol fatty acid ester, diacetyl tartaric acid monoglyceride/diglyceride, sodium stearyl lactate, sucrose fatty acid ester, succinic acid glycerin fatty acid ester, polysorbate, polyglycerol fatty acid ester, fatty acid sorbitol anhydride ester, and lactic acid and fatty glyceride. The preparation method of the high-fat powder grease adopts spray drying. The fat content of the high-fat powder grease is high, the product stability is good and the grease needed by products can be provided when the high-fat powder grease is used for baked products; since the provided grease is in a powder state, the grease can be very easily mixed with flour and the like and the use is greatly facilitated; and at the same time, the high-fat powder grease simultaneously has a performance of shortening and the shortening capacity of the baked products can be remarkably improved.

The invention discloses a hydrating and skin rejuvenating mask and a preparation method thereof, and belongs to the technical field of masks. The hydrating and skin rejuvenating mask comprises the following raw materials in percentage by weight: 3 to 10 percent of glycerinum, 1.5 to 4.5 percent of butanediol, 1 to 4 percent of deep-sea fish collagen peptide, 3 to 8 percent of mycose, 0.05 to 2 percent of squalane, 0.15 to 2 percent of sodium hyaluronate, 1 to 5 percent of propylene glycol, 0.02 to 0.35 percent of xanthan gum, 0.02 to 0.45 percent of hydrogenated castor oil, 0.02 to 2 percent of polysorbate, 0.01 to 1 percent of phenoxyethanol, 0.01 to 0.5 percent of methylparaben, 0.1 to 2 percent of beta-glucan, 0.01 to 0.5 percent of a grape seed extract, 0.01 to 3 percent of an aloe extract, 0.01 to 1 percent of dipotassium glycyrrhizinate and the balance of deionized water. The mask provided by the invention promotes the absorption of water by the skin, is favorable for the skin topreserve moisture for a long time, is non-irritant and has a good effect of moisturizing skin.

The invention relates to the technical field of medicines, and specifically relates to pomalidomide nanoparticle and preparation and a preparation method thereof. The pomalidomide nanoparticle comprises the following components in parts by weight: 0.5 to 1.5 parts of pomalidomide, and 10 to 100 parts of nano-carrier, wherein the nano-carrier comprises one or more of lecithin, povidone, polyalkylcyano-acrylate, acrylamide, N, N-methylene diacrylic acid amine, polysorbate, sorbitan monolaurate, lauryl alcohol polyoxyethylene, sodium dodecyl sulfate, poloxamer, polyethylene glycol, cyclodextrin and cyclodextrin derivates. The particle size of omalidomide nanoparticle is at nanometer level; on that basis, the prepared pomalidomide preparation is high in dissolution rate.

The invention relates to a pantoprazole sodium medicinal composition which is prepared by dissolving 40g of pantoprazole sodium, 160g of mannitol, 120-300g of polysorbate and 200-600g of 2-hydroxypropyl-beta-cyclodextrin in 2,000ml of injection water and then freeze-drying. The pantoprazole sodium medicinal composition provided by the invention has the advantages of good stability and low hygroscopicity; and after prepared into injection, the pantoprazole sodium medicinal composition has the advantages that the relatively long-time stability can be maintained, and the medicine safety is improved.